Clinical Validation of Effectiveness of Immunace Forte? & Ultra D3? Improving Immunogenicity of COVID-19 Vaccine in Healthy Individuals

Background: An effective immune response requires an adequate host nutritional status. The present clinical trial aims at exploring safety and effectiveness of Immuno adjuvant medication like Immunace forte? and Ultra D3? tablets administered with Covishield Vaccine in improving immunogenicity of the vaccine. Trial design: Trial was randomized controlled, parallel arm with 60 patients (n = 30/group). Methodology: The primary objective of the study was evaluating SARS-CoV-2 serum neutralizing antibody levels (Total Covid specific antibodies) in both groups and COVID 19 incidence. Results: At baseline the Covid Specific antibody levels in both group were comparable. At 1st assessment (after 12 weeks of first vaccine dose) the antibody levels in treatment group were increased by 7% whereas 31.37% reduction in control group. At assessment 2 (after 3 weeks of second vaccine dose) the antibody levels in treatment group were increased by 17.45% whereas reduced by 38.50 % in control group. Two subjects from control group demonstrated the COVID 19 incidence verses no subject from treatment group.6 subjects produced symptoms like cold, cough and mild fever from control group. Conclusion: The present study was instrumental in demonstrating the effectiveness of multi-nutrient supplementation in order to improve the response to vaccine in COVID 19.